VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
THC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
THCTenet Healthcare Corporation
$258.62$22.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTHCFinancials

Tenet Healthcare Corporation (THC) Income Statement

30Y historyFree accessUpdated daily

Revenue growth reaccelerated to 6.8% in Q2 2026 with operating margin expanding to 18.2%, though gross margin volatility (18.2% vs 82.3% year-ago) reflects accounting treatment shifts.

Income StatementBalance SheetCash FlowRatios

THC Income Statement

Annual statement

THC Income Statement

Tenet Healthcare Corporation (THC) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03May'02May'00May'99May'98May'97May'96May'95
Sales/Revenue21.81B21.31B20.66B20.55B19.17B19.48B17.64B18.48B18.31B19.18B19.62B18.63B16.6B11.09B9.12B8.65B8.27B9.01B8.59B8.08B8.45B8.33B8.77B10.05B13.91B12.05B11.41B10.88B9.89B8.69B7.71B
Revenue Growth %5.43%3.12%0.57%7.17%-1.6%10.46%-4.54%0.91%-4.52%-2.25%5.3%12.23%49.75%21.58%5.37%4.71%-8.31%5%6.21%-4.38%1.53%-5.04%-12.77%-27.75%15.43%5.6%4.91%9.95%13.85%12.78%132.25%
Cost of Goods Sold15.95B3.78B12.46B12.74B12.13B12.22B11.41B11.77B11.65B12.38B12.48B11.95B10.65B7.16B5.81B1.55B1.54B5.43B5.29B5.02B5.31B5.32B5.34B004.28B4.12B3.87B3.45B7.83B6.35B
COGS % of Revenue-17.74%60.28%62.02%63.24%62.7%64.68%63.67%63.63%64.58%63.61%64.15%64.16%64.53%63.7%17.89%18.66%60.2%61.62%62.08%62.78%63.93%60.96%--35.51%36.1%35.54%34.83%90.14%82.39%
Gross Profit5.86B17.53B8.21B7.8B7.05B7.27B6.23B6.71B6.66B6.79B7.14B6.68B5.95B3.93B3.31B7.11B6.72B3.59B3.29B3.06B3.15B3B3.42B007.77B7.29B7.01B6.45B857M1.36B
Gross Margin %26.87%82.26%39.72%37.98%36.76%37.3%35.32%36.33%36.37%35.42%36.39%35.85%35.84%35.47%36.3%82.11%81.34%39.8%38.38%37.92%37.22%36.07%39.04%--64.49%63.9%64.46%65.17%9.86%17.61%
Gross Profit Growth %-113.55%5.18%10.74%-3.03%16.64%-7.19%0.81%-1.97%-4.86%6.89%12.29%51.32%18.79%-53.42%5.7%87.37%8.89%7.5%-2.57%4.76%-12.27%---100%6.57%4.01%8.75%652.51%-36.85%117.82%
Operating Expenses2.2B14.09B2.25B5.29B4.71B4.4B4.24B5.18B5.02B5.68B5.89B5.6B5.03B3.27B2.56B6.45B6.09B3.59B3.29B3.06B3.15B3B3.42B10.05B13.91B7.77B7.29B7.01B6.45B857M1.36B
OpEx % of Revenue-66.12%10.9%25.77%24.59%22.57%24.05%28.02%27.43%29.62%30.04%30.07%30.27%29.48%28.13%74.57%73.67%39.8%38.38%37.92%37.22%36.07%39.04%100%100%64.49%63.9%64.46%65.17%9.86%17.61%
Selling, General & Admin6.61B8.71B8.8B418M412M412M403M344M00315M248M234M186M156M00002.61B2.54B2.88B3.44B12.15B5.53B5.36B5.16B4.64B000
SG&A % of Revenue-40.85%42.59%2.03%2.15%2.11%2.28%1.86%--1.61%1.33%1.41%1.68%1.71%----32.34%30.1%34.6%39.19%120.88%39.74%44.46%45.16%42.65%---
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses-3M5.39B-6.55B4.88B4.3B3.98B3.84B4.83B5.02B5.68B5.58B5.36B4.79B3.08B02.44B2.26B3.59B3.29B451M695M588M426M949M2.8B2.24B1.94B1.86B1.81B857M1.36B
Operating Income3.66B3.44B5.96B2.51B2.33B2.87B1.99B1.54B1.64B1.11B1.25B1.08B925M663M749M653M634M596M2.3B2.17B-732M-16M-1.2B-991M2.09B1.55B1.4B1.3B1.35B414M938M
Operating Margin %16.8%16.14%28.82%12.22%12.17%14.73%11.28%8.32%8.94%5.8%6.36%5.78%5.57%5.98%8.21%7.55%7.67%6.61%26.74%26.9%-8.66%-0.19%-13.71%-9.86%15.05%12.83%12.28%11.97%13.63%4.76%12.17%
Operating Income Growth %--42.26%137.29%7.59%-18.74%44.34%29.41%-6.11%47.08%-10.75%15.78%16.43%39.52%-11.48%14.7%3%6.38%-74.04%5.61%396.99%-4475%98.67%-21.29%-147.33%35.36%10.34%7.68%-3.48%225.85%-55.86%119.16%
EBITDA4.56B4.3B6.77B3.38B3.17B3.73B2.85B2.39B2.44B1.98B2.1B1.87B1.77B1.21B1.18B1.07B1.06B982M2.67B2.54B-390M366M-814M-520M2.65B2.08B1.96B1.76B1.79B735M1.13B
EBITDA Margin %20.89%20.19%32.78%16.45%16.55%19.12%16.13%12.92%13.32%10.34%10.69%10.06%10.68%10.9%12.93%12.32%12.81%10.89%31.09%31.37%-4.61%4.4%-9.28%-5.17%19.03%17.26%17.15%16.19%18.11%8.46%14.7%
EBITDA Growth %2.4%-36.49%100.41%6.49%-14.81%30.92%19.23%-2.13%23%-5.44%11.9%5.64%46.85%2.46%10.6%0.66%7.84%-63.21%5.24%750.26%-206.56%144.96%-56.54%-119.64%27.31%6.23%11.12%-1.67%143.81%-35.13%80.99%
D&A (Non-Cash Add-back)893M863M818M870M841M855M857M850M802M870M850M797M849M545M430M413M425M386M373M362M342M382M388M471M554M533M556M460M443M321M195M
EBIT4.17B3.62B6.07B2.52B2.23B2.81B1.67B1.3B1.63B927M1.23B1.06B901M316M746M539M582M650M472M323M-732M-16M-1.2B-991M2.09B1.55B1.4B1.3B1.35B414M938M
Net Interest Income-820M-821M-826M-901M-890M-923M-1B-985M-1B-1.03B-979M-912M-754M-474M-412M-375M-424M-445M-418M-419M00000000000
Interest Income0000000000000000000000000000000
Interest Expense820M821M826M901M890M923M1B985M1B1.03B979M912M754M474M412M375M424M445M418M439M1.35B932M2.51B2.49B518M1.11B1.16B1.03B607M062M
Other Income/Expense201M-639M-708M-893M-988M-983M-1.32B-1.22B-1.01B-1.21B-999M-933M-778M-821M-415M-489M-476M-391M-2.24B-2.27B-345M-344M-357M-403M-333M-405M-784M-828M-702M-435M-57M
Pretax Income3.87B2.8B5.25B1.62B1.34B1.89B671M320M629M-101M248M144M147M-158M334M164M158M205M54M-96M-1.08B-360M-1.56B-1.39B1.76B1.14B618M474M647M-21M881M
Pretax Margin %17.72%13.14%25.4%7.87%7.01%9.69%3.8%1.73%3.43%-0.53%1.26%0.77%0.89%-1.43%3.66%1.9%1.91%2.27%0.63%-1.19%-12.74%-4.32%-17.78%-13.87%12.66%9.47%5.41%4.36%6.54%-0.24%11.43%
Income Tax691M433M1.18B306M344M411M-97M160M173M219M67M68M49M-65M125M61M-977M-23M-25M-61M-262M-88M295M-274M736M464M278M225M269M52M383M
Effective Tax Rate %17.88%15.46%22.56%18.92%25.58%21.77%-14.46%50%27.5%-216.83%27.02%47.22%33.33%41.14%37.43%37.2%-618.35%-11.22%-46.3%63.54%24.33%24.44%-18.92%19.66%41.79%40.63%44.98%47.47%41.58%-247.62%43.47%
Net Income2.24B1.41B3.2B611M411M914M399M-215M104M-704M-192M-140M12M-134M152M82M1.14B187M25M-89M-803M-724M-2.81B-1.56B785M643M302M249M261M-254M450M
Net Margin %10.27%6.6%15.49%2.97%2.14%4.69%2.26%-1.16%0.57%-3.67%-0.98%-0.75%0.07%-1.21%1.67%0.95%13.83%2.07%0.29%-1.1%-9.5%-8.7%-32%-15.56%5.64%5.33%2.65%2.29%2.64%-2.92%5.84%
Net Income Growth %51.01%-56.03%423.73%48.66%-55.03%129.07%285.58%-306.73%114.77%-266.67%-37.14%-1266.67%108.96%-188.16%85.37%-92.83%511.23%648%128.09%88.92%-10.91%74.2%-79.41%-299.24%22.08%112.91%21.29%-4.6%202.76%-156.44%145.9%
Net Income (Continuing)3.17B2.37B4.06B1.31B1B1.48B768M160M456M-320M181M76M98M-93M0103M1.14B228M79M-35M-815M-272M-1.85B-1.12B1.02B678M340M249M378M-73M498M
Discontinued Operations00001M-1M011M3M002M000017M00000000000000
Minority Interest4.04B4.75B4.38B3.9B3.47B3.23B2.86B2.36B2.23B2.55B3.06B2.53B535M370M91M85M53M51M0000000000000
EPS (Diluted)26.6915.4932.705.713.798.423.75-2.241.07-7.00-1.93-1.410.12-1.321.300.488.161.480.20-0.76-6.84-6.16-24.08-9.606.245.252.562.113.24-2.244.08
EPS Growth %66.01%-52.63%472.68%50.66%-54.99%124.53%267.41%-309.35%115.29%-262.69%-36.88%-1275%109.09%-201.54%170.83%-94.12%451.35%640%126.32%88.89%-11.04%74.42%-150.83%-253.85%18.86%105.08%21.33%-34.88%244.64%-154.9%67.9%
EPS (Basic)-15.6133.026.013.848.553.80-2.241.09-7.00-1.93-1.410.12-1.321.350.499.241.520.20-0.76-6.84-6.16-24.08-9.606.405.362.592.133.28-2.244.16
Diluted Shares Outstanding83.96M90.83M97.88M104.8M110.52M108.57M106.26M103.4M103.88M100.59M99.32M99.17M100.29M101.65M108.93M121.3M140.16M126.82M119.65M118.35M117.71M117.22M116.56M116.6M122.68M118.09M117.52M116.8M114.06M80.09M75.41M
Basic Shares Outstanding83.52M90.15M96.9M101.64M106.93M106.83M105.01M103.4M102.11M100.57M99.32M99.17M97.8M101.65M104.2M117.18M121.08M120.06M119.09M118.35M117.71M117.22M116.56M116.6M119.91M116.99M116.27M115.02M113.95M77.42M66.31M
Dividend Payout Ratio----------------0.7%3.74%-------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

USPI concentration and revenue deferrals

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Growth Reaccelerates on Mix Shift

Tenet's revenue growth accelerated to 6.8% in Q2 2026, up from 2.8% in Q1, driven by higher-acuity services and USPI expansion, per reported financials.

The sequential acceleration in revenue growth, from 2.8% in Q1 2026 to 6.8% in Q2 2026, suggests that the company's strategic focus on higher-acuity and ambulatory services is gaining traction. This is supported by the peer context where HCA's growth is 7.1%, indicating Tenet is now growing in line with its largest competitor. However, the recent risk flag notes revenue deferral dynamics and M&A activity may distort reported growth, so investors should monitor organic growth quality.

Gross Margin Volatility Masks Core Strength

Gross margin swung from 82.3% in Q2 2025 to 18.2% in Q2 2026, reflecting accounting treatment of labor costs, but operating margin improved to 18.2%, per SEC filings.

The dramatic fluctuation in gross margin, from 82.3% in Q2 2025 to 18.2% in Q2 2026, appears to be a function of how labor costs are classified, as the company intelligence notes that the 82% figure likely excludes labor. The more stable operating margin, which has ranged between 14.9% and 21.3% over the past year, indicates that the underlying cost structure is being managed effectively. The Q2 2026 operating margin of 18.2% is above the peer average, suggesting Tenet is extracting operational efficiencies from its mix shift toward USPI.

Operating Leverage Evident in EPS Beat

Q2 2026 EPS of $9.84 beat consensus by 32%, with operating income growing 21.5% year-over-year on 6.8% revenue growth, indicating strong operating leverage, as reported.

The 21.5% year-over-year growth in operating income, against a 6.8% revenue increase, demonstrates that Tenet is scaling its fixed-cost base effectively. This operating leverage is also reflected in the net margin expansion from 5.5% in Q2 2025 to 14.7% in Q2 2026, a significant improvement. The company's ability to convert revenue growth into disproportionate profit growth suggests that the higher-margin ambulatory segment is becoming a larger part of the mix, which may be sustainable if the trend continues.

Earnings Quality Boosted by One-Time Items

Q2 2026 net income of $826M includes a $25M SBC charge, but the 14.7% net margin is inflated by a $3.3B operating income in Q1 2024, per financial statements.

The reported net margin of 14.7% in Q2 2026 is unusually high compared to the trailing average of around 6-8%, suggesting that the quarter may include non-recurring gains or favorable items. The Q1 2024 quarter, which showed an operating margin of 61.2% and net income of $2.2B, is clearly an outlier, likely due to a one-time gain, and should be excluded when assessing core earnings power. Investors should normalize for such items to gauge the sustainability of the current earnings level.

Labor Costs Drive Expense Discipline

SG&A expenses remained flat at $2.2B in Q2 2026 despite revenue growth, indicating tight cost control, but labor costs remain the largest expense line, per reported data.

The stability of SG&A at $2.2B across recent quarters, even as revenue grew, suggests that management is effectively controlling overhead costs. However, the company intelligence highlights that salaries and benefits are the largest expense, and the gross margin volatility indicates that labor costs are a significant variable. The recent earnings beat was attributed to expense discipline, but investors should monitor for potential wage inflation pressures that could erode margins if labor markets tighten.

Q1 2024 Marks Operational Inflection

Q1 2024 operating income of $3.3B and net income of $2.2B represent a clear inflection point, likely driven by one-time gains, as subsequent quarters normalized to ~$800M, per filings.

The Q1 2024 quarter stands out as a clear inflection point in the income statement history, with operating income of $3.3B and net margin of 40.1%, far exceeding any other period. This appears to be driven by a one-time event, possibly an asset sale or legal settlement, as the following quarters reverted to more typical operating income levels of $800M-$1.1B. The lasting impact is that it may have distorted the year-over-year comparisons, making subsequent growth rates appear weaker than they actually are.

USPI Concentration and Revenue Deferrals Pose Risks

The reliance on USPI for margin expansion and the noted revenue deferral dynamics could mean reported growth overstates underlying momentum, as per recent risk flags.

Short-sellers might argue that Tenet's impressive margin expansion is overly dependent on the USPI segment, which could face disruption from regulatory changes or integration issues. Additionally, the recent risk flag about revenue deferrals suggests that some reported revenue may be pulled forward, inflating growth rates. If organic growth is weaker than reported, the stock could be vulnerable to a de-rating. Investors should closely track same-facility volumes and cash conversion to validate the quality of earnings.

THC — Frequently Asked Questions

Quick answers to the most common questions about buying THC stock.

What was Tenet Healthcare Corporation's (THC) revenue in 2025?

For fiscal year 2025, Tenet Healthcare Corporation (THC) reported total revenue of $21.31B. This represents a 176.5% increase compared to $7.71B in 1995.

Is Tenet Healthcare Corporation (THC) profitable?

Tenet Healthcare Corporation (THC) is profitable, generating $1.41B in net income for the fiscal year ending 2025 with a net profit margin of 6.6%.

What is Tenet Healthcare Corporation's operating profit margin?

Tenet Healthcare Corporation (THC) reported an operating income of $3.44B, resulting in an operating profit margin of 16.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Tenet Healthcare Corporation's gross profit and gross margin?

Tenet Healthcare Corporation (THC) generated $17.53B in gross profit for the year, representing a gross profit margin of 82.3%. This demonstrates the company's core pricing power and production efficiency.